Evidence map›Paper›PMID 37245855›Full record

ArticleJournal of substance use and addiction treatment2023

Psychometric properties of the Treatment Effectiveness Assessment in methamphetamine use disorder.

Hoa T Vo, Alexandra Kulikova, Taryn L Mayes, Thomas Carmody, Steve Shoptaw, Walter Ling, Joseph M Trombello, Madhukar H Trivedi

Open access · greenAbstract read
In one paragraph

Article in Journal of substance use and addiction treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hoa T VoCenter for Depression Research and Clinical Care, Department of Psychiatry and Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA.
Alexandra KulikovaCenter for Depression Research and Clinical Care, Department of Psychiatry and Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA.
Taryn L MayesCenter for Depression Research and Clinical Care, Department of Psychiatry and Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA.
Thomas CarmodyCenter for Depression Research and Clinical Care, Department of Psychiatry and Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA.
Steve ShoptawUniversity of California Los Angeles, Los Angeles, CA, USA.
Walter LingUniversity of California Los Angeles, Los Angeles, CA, USA.
Joseph M TrombelloCenter for Depression Research and Clinical Care, Department of Psychiatry and Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA.
Madhukar H TrivediCenter for Depression Research and Clinical Care, Department of Psychiatry and Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA. Electronic address: Madhukar.Trivedi@UTSouthwestern.edu.
Southwestern Medical Center · USUniversity of California, Los Angeles · USSouthwestern Medical CenterThe University of Texas Southwestern Medical Center · US

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Project-004UG1DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Steven J Shoptaw, MADHUKAR H. TRIVEDI · 2015 to 2026
$71.6M
Suicide Prediction and Prevention for People at Risk for Opioid Use DisorderUG1DA040316 · NIDA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI GAVIN BART · 2015 to 2026
$42.2M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
Southern Consortium Node of the Clinical Trials Network (Varenicline)UG1DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KATHLEEN T. BRADY, Kelly S. Barth · 2015 to 2026
$24.8M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Concept ProjectU10DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI TRIVEDI, MADHUKAR H. · 2005 to 2015
$22.6M
NIDA NIH HHS HHSN271201400028CNIDA NIH HHS HHSN271201500065CNIDA NIH HHS U10 DA015815NIDA NIH HHS U10 DA020024NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013727NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1 DA020024NIDA NIH HHS UG1 DA040316
6 · The paper itself

Abstract

introductionThe ability for people living with stimulant use disorder to live meaningful lives requires not only abstinence from addictive substances, but also healthy engagement with their community, lifestyle practices, and overall health. The Treatment Effectiveness Assessment (TEA) assesses components of recovery consisting of four functional domains: substance use, health, lifestyle, and community. This secondary data analysis of 403 participants with severe methamphetamine use disorder tested the reliability and validity of the TEA.

methodsParticipants were enrolled in the Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for methamphetamine use disorder. The study used total TEA and domain scores at baseline to assess factor structure and internal consistency, as well as construct validity related to substance cravings (visual analog scale [VAS]), quality of life (quality-of-life assessment [QoL]), mental health (Patient Health Questionnaire-9 [PHQ-9], Concise Health Risk Tracking Scale Self-Report [CHRT-SR

resultsIndividual TEA items showed moderate to large correlations with each other (r = 0.27-0.51; p < .001), and strong correlations to the total score (r = 0.69-0.78; p < .001). Internal consistency was strong (coefficient α = 0.73 [0.68-0.77]; coefficient ω = 0.73 [0.69-0.78]). Construct validity was acceptable, with the strongest correlation between the TEA Health item and the general health status item on the QoL (r = 0.53, p < .001).

conclusionsTEA has acceptable levels of reliability and validity supporting prior similar findings in a sample of participants with moderate to severe methamphetamine use disorder. Results from this study provide support for its use in assessing clinically meaningful changes beyond simply reduced substance use.

Indexed as

MethamphetamineSubstance-Related DisordersHumansPsychometricsQuality of LifeReproducibility of ResultsTreatment OutcomeMethamphetamineFunctioningMethamphetamine use disorderPsychometric analysisStimulant useSubstance use disorder

Identifiers

PMID37245855
PMCPMC10977640
OpenAlexW4378364478

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.